These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34923158)

  • 1. Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt.
    Seadawy MG; Gad AF; Abo-Elmaaty SA; Hassan MG
    Infect Genet Evol; 2022 Jan; 97():105191. PubMed ID: 34923158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
    Focosi D; Maggi F
    Rev Med Virol; 2021 Nov; 31(6):e2231. PubMed ID: 33724631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
    Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
    mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
    Bui NN; Lin YT; Huang SH; Lin CW
    Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification, propagation and molecular characterization of SARS-CoV-2 delta variant isolated from Egyptian COVID-19 patients.
    Alotaibi B; El-Masry TA; Seadawy MG; El-Harty BE; Saleh A; Gad AF; El-Hosseny MF; Mahran YF; El-Bouseary MM
    Infect Genet Evol; 2022 Jun; 100():105278. PubMed ID: 35367360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 evolution during treatment of chronic infection.
    Kemp SA; Collier DA; Datir RP; Ferreira IATM; Gayed S; Jahun A; Hosmillo M; Rees-Spear C; Mlcochova P; Lumb IU; Roberts DJ; Chandra A; Temperton N; ; ; Sharrocks K; Blane E; Modis Y; Leigh KE; Briggs JAG; van Gils MJ; Smith KGC; Bradley JR; Smith C; Doffinger R; Ceron-Gutierrez L; Barcenas-Morales G; Pollock DD; Goldstein RA; Smielewska A; Skittrall JP; Gouliouris T; Goodfellow IG; Gkrania-Klotsas E; Illingworth CJR; McCoy LE; Gupta RK
    Nature; 2021 Apr; 592(7853):277-282. PubMed ID: 33545711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
    Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
    Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
    Dupont L; Snell LB; Graham C; Seow J; Merrick B; Lechmere T; Maguire TJA; Hallett SR; Pickering S; Charalampous T; Alcolea-Medina A; Huettner I; Jimenez-Guardeño JM; Acors S; Almeida N; Cox D; Dickenson RE; Galao RP; Kouphou N; Lista MJ; Ortega-Prieto AM; Wilson H; Winstone H; Fairhead C; Su JZ; Nebbia G; Batra R; Neil S; Shankar-Hari M; Edgeworth JD; Malim MH; Doores KJ
    Nat Microbiol; 2021 Nov; 6(11):1433-1442. PubMed ID: 34654917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing monoclonal antibodies for treatment of COVID-19.
    Taylor PC; Adams AC; Hufford MM; de la Torre I; Winthrop K; Gottlieb RL
    Nat Rev Immunol; 2021 Jun; 21(6):382-393. PubMed ID: 33875867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
    Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
    Front Immunol; 2021; 12():711915. PubMed ID: 34276706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
    Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
    Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
    Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.